Buy Drugs Online:
Drugs Information:
Drugs List

1. Name Of The Medicinal Product

Difflam Cream

or

Difflam-P Cream

2. Qualitative And Quantitative Composition

Each tube of Difflam Cream/ Difflam-P Cream contains Benzydamine Hydrochloride 3% w/w.

3. Pharmaceutical Form

Cream.

4. Clinical Particulars

4.1 Therapeutic Indications

Difflam Cream/ Difflam-P Cream is a topical analgesic and non-steroidal anti-inflammatory agent.

It is recommended as a short-term treatment for the relief of symptoms associated with painful inflammatory conditions of the musculo-skeletal system, including:

Acute inflammatory disorders such as myalgia and bursitis.

Traumatic conditions such as sprains, strains, contusions and the after-effects of fractures.

Difflam Cream/ Difflam-P Cream is well absorbed through the skin and has been shown to have anti-inflammatory and local anaesthetic actions.

4.2 Posology And Method Of Administration

Difflam Cream/ Difflam-P Cream should be massaged lightly into the affected area. Depending on the size of the site to be treated, 35 - 85 mm (1 - 2 g) should be applied three times daily and at the discretion of the doctor, up to six times daily in more severe conditions. It is recommended that treatment be limited to not more than ten days.

ELDERLY:

No special dosage recommendations are made for elderly patients.

4.3 Contraindications

Difflam Cream is contraindicated in patients with known hypersensitivity to any of the ingredients.

4.4 Special Warnings And Precautions For Use

To avoid possible irritation, Difflam Cream/ Difflam-P Cream

1. Name Of The Medicinal Product

Desferal® Vials, 500mg or 2g.

2. Qualitative And Quantitative Composition

Each vial contains desferrioxamine mesilate 500mg or 2g.

3. Pharmaceutical Form

A sterile, lyophilised powder available in vials containing 500mg or 2g of desferrioxamine mesilate.

4. Clinical Particulars

4.1 Therapeutic Indications

Treatment for chronic iron overload, e.g.

• transfusional haemosiderosis in patients receiving regular transfusions e.g. thalassaemia major

• primary and secondary haemochromatosis in patients in whom concomitant disorders (e.g. severe anaemia, hypoproteinaemia, renal or cardiac failure) preclude phlebotomy.

Treatment for acute iron poisoning.

For the diagnosis of iron storage disease and certain anaemias.

Aluminium overload - In patients on maintenance dialysis for end stage renal failure where preventative measures (e.g. reverse osmosis) have failed and with proven aluminium-related bone disease and/or anaemia, dialysis encephalopathy; and for diagnosis of aluminium overload.

4.2 Posology And Method Of Administration

Desferal may be administered parenterally.

For parenteral administration:

The drug should preferably be employed in the form of a 10% solution, e.g. 500 mg: by dissolving the contents of one 500mg vial in 5ml of water for injection or 2 g: by dissolving the contents of one 2 g vial in 20 ml of water for injection. When administered subcutaneously the needle should not be inserted too close to the dermis. The 10% Desferal solution can be diluted with routinely employed infusion solutions (saline, glucose, dextrose or dextrose-saline), although these should not be us

1. Name Of The Medicinal Product

Dalacin® T Topical Solution

Clindamycin Phosphate Topical Solution.

2. Qualitative And Quantitative Composition

One ml of Dalacin T Topical Solution contains the equivalent of 10 mg Clindamycin.

For excipients see Section 6.1 ('List of excipients').

3. Pharmaceutical Form

Topical solution.

Clear colourless aqueous solution.

4. Clinical Particulars

4.1 Therapeutic Indications

Dalacin T Topical Solution is indicated in the treatment of acne vulgaris

4.2 Posology And Method Of Administration

Apply a thin film of Dalacin T Topical Solution twice daily to the affected area.

4.3 Contraindications

Topical clindamycin is contraindicated in individuals with a history of hypersensitivity to clindamycin or lincomycin. Clindamycin topical is contraindicated in individuals with a history of inflammatory bowel disease or a history of antibiotic-associated colitis.

4.4 Special Warnings And Precautions For Use

Products containing benzoyl peroxide should not be used concurrently with Dalacin T Topical Solution.

Oral and parenteral clindamycin, as well as most other antibiotics, have been associated with severe pseudomembranous colitis. Post-marketing studies, however, have indicated a very low incidence of colitis with Dalacin T Topical Solution. The physician should, nonetheless, be alert to the development of antibiotic associated diarrhoea or colitis. If significant or prolonged diarrhoea occurs, the product should be discontinued immediately.

Diarrhoea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and pare

1. Name Of The Medicinal Product

Diclofenac potassium 12.5mg Tablets

Double Action Pain Relief 12.5mg Tablets

2. Qualitative And Quantitative Composition

Each tablet contains 12.5mg Diclofenac potassium.

For a full list of excipients, see section 6.1

3. Pharmaceutical Form

Film coated Tablet

White round, unscored biconvex film coated tablet, 5mm diameter, with 'I' marked on one side.

4. Clinical Particulars

4.1 Therapeutic Indications

Short term relief of headache, dental pain, period pain, rheumatic pain, muscular pain, backache and the symptoms of colds and flu including fever.

4.2 Posology And Method Of Administration

Adults and children aged 14 years and over:

Initially two tablets, followed by one or two tablets every 4 to 6 hours as needed. No more than 6 tablets (75 mg) should be taken in any 24 hour period.

Double Action Pain Relief 12.5mg Tablets should not be used for longer than 3 days. If symptoms persist or worsen consult your doctor.

To be taken preferably with or after food, swallowed whole with a drink of water.

Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to relieve symptoms (see section 4.4).

Children and Adolescents:

Double Action Pain Relief 12.5mg Tablets are not to be used in children and adolescents under 14 years of age.

4.3 Contraindications

Known hypersensitivity to diclofenac or to any of the excipients.

Active or histo

1. Name Of The Medicinal Product

Dacarbazine medac 100 mg, Powder for solution for injection or infusion

Dacarbazine medac 200 mg, Powder for solution for injection or infusion

Dacarbazine medac 500 mg, Powder for solution for infusion

Dacarbazine medac 1000 mg, Powder for solution for infusion

2. Qualitative And Quantitative Composition

Each single-dose vial of Dacarbazine medac 100 mg (-200 mg, -500 mg, -1000 mg) contains 100 mg (200 mg, 500 mg, 1000 mg) dacarbazine (as dacarbazine citrate, formed in situ).

After reconstitution, Dacarbazine medac 100 mg (-200 mg) contains 10 mg/ml dacarbazine (see 6.6 a).

After reconstitution and final dilution, Dacarbazine medac 500 mg (-1000 mg) contains

1.4 – 2.0 mg/ml (2.8 – 4.0 mg/ml) dacarbazine (see 6.6 b).

For excipients, see section 6.1.

3. Pharmaceutical Form

Dacarbazine medac 100 mg (-200 mg-): Powder for solution for injection or infusion.

Dacarbazine medac 500 mg (-1000 mg-): Powder for solution for infusion.

Dacarbazine medac is a white or pale yellow powder.

4. Clinical Particulars

4.1 Therapeutic Indications

Dacarbazine is indicated for the treatment of patients with metastasized malignant melanoma.

Further indications for dacarbazine as part of a combination chemotherapy are:

- advanced Hodgkin's disease,

- advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma).

4.2 Posology And Method Of Administration

The use of dacarbazine should be confined to physicians experienced in oncology or haematology respectively.

Dacarbazine is sensitive to light exposure. All re

1. Name Of The Medicinal Product

Diamorphine Hydrochloride 100mg for Injection

2. Qualitative And Quantitative Composition

Each ampoule contains 100mg of diamorphine hydrochloride.

For full list of excipients, see section 6.1.

3. Pharmaceutical Form

A white to off-white, sterile, freeze dried powder of Diamorphine Hydrochloride BP for reconstitution for injection.

4. Clinical Particulars

4.1 Therapeutic Indications

Diamorphine may be used in the treatment of severe pain associated with surgical procedures, myocardial infarction or pain in the terminally ill and for the relief of dyspnoea in acute pulmonary oedema.

4.2 Posology And Method Of Administration

Diamorphine may be given by the intramuscular, intravenous or subcutaneous routes. Glucose intravenous infusion is the preferred diluent, particularly when the drug is administered by a continuous infusion pump over 24 to 48 hours, although it is also compatible with sodium chloride intravenous infusion.

The dose should be suited to the individual patient.

Adults:

Acute pain, 5mg repeated every four hours if necessary (up to 10mg for heavier, well muscled patients) by subcutaneous or intramuscular injection. By slow intravenous injection, one quarter to one half the corresponding intramuscular dose.

Chronic pain, 5-10mg regularly every four hours by subcutaneous or intramuscular injection. The dose may be increased according to individual needs.

Myocardial infarction, 5mg by slow intravenous injection (1mg/minute) followed by a further 2.5mg to 5mg if necessary.

Acute pulmonary oedema, 2.5mg to 5mg by slow intravenous injection (1mg/minute).

1. Name Of The Medicinal Product

Dexamethasone 3.3 mg/ml solution for injection

2. Qualitative And Quantitative Composition

3.32 mg of dexamethasone (dexamethasone base) in 1 ml solution for injection

6.64 mg of dexamethasone (dexamethasone base) in 2 ml solution for injection

Each ml of solution for injection contains 4.00 mg of dexamethasone phosphate (as 4.37 mg dexamethasone sodium phosphate) equivalent to 3.32 mg of dexamethasone base.

For full list of excipients, see section 6.1.

3. Pharmaceutical Form

Solution for injection

Clear and colourless solution

4. Clinical Particulars

4.1 Therapeutic Indications

Corticosteroid

For use in certain endocrine and non-endocrine disorders responsive to corticosteroid therapy

Systemic administration

Dexamethasone 3.3 mg/ml solution for injection is recommended for systemic administration by intravenous or intramuscular injection when oral therapy is not feasible or desirable in the following conditions.

Endocrine disorders

Primary or secondary adrenocortical insufficiency

(Hydrocortisone or cortisone is the first choice, but synthetic analogues may be used with mineralocorticoids where applicable and, in infancy, mineralocorticoid supplementation is particularly important)

Non-endocrine disorders

Dexamethasone 3.3 mg/ml solution for injection may be used in the treatment of non-endocrine corticosteroid-responsive conditions, including:

1. Name Of The Medicinal Product

Dalmane 15 mg Capsules

2. Qualitative And Quantitative Composition

  ICN
Capsules with opaque grey cap and opaque yellow body with 15 printed in red on both cap and body, containing 16.4 mg flurazepam monohydrochloride (equivalent to 15 mg flurazepam).

3. Pharmaceutical Form

Dalmane capsules 15 mg

4. Clinical Particulars

4.1 Therapeutic Indications

Short-term treatment of insomnia when it is severe, disabling or subjecting the individual to extreme distress. Dalmane is helpful in overcoming difficulties in getting to sleep and also in the problem of frequent nocturnal awakenings. Its properties make it particularly indicated where the total duration of sleep is less than adequate.

An underlying cause for insomnia should be sought before deciding upon the use of benzodiazepines for symptomatic relief.

Benzodiazepines are not recommended for the primary treatment of psychotic illness.

4.2 Posology And Method Of Administration

Adults

The dosage of Dalmane should be determined on an individual basis taking into account the severity of the insomnia and the patient's response to treatment. Dosage is important in determining the duration of effect and the occurrence of residual effects. For most patients the optimum dose if 15 mg – this will ensure a full night's sleep with minimal residual effects on wakening. Patients with severe insomnia may require 30 mg but residual effects on awakening, associated with an anxiolytic effect, are more frequent

1. Name Of The Medicinal Product

DOLPIN Haloperidol Oral Solution BP 5 mg/5 ml

2. Qualitative And Quantitative Composition

Each 5 ml contains 5 mg of Haloperidol

3. Pharmaceutical Form

Oral Solution

4. Clinical Particulars

4.1 Therapeutic Indications

Psychotic disorders - schizophrenia, mania and hypomania, especially paranoid psychoses. Mental or behavioural problems such as aggression, hyperactivity and self - mutilation in the mentally retarded. As an adjunct to the short term management of moderate to severe psychomotor agitation, excitement, violent or dangerously impulsive behaviour. Gilles de la Tourette syndrome, intractable hiccup and severe tics. Childhood behaviour disorders, especially when associated with hyperactivity and aggression. Restlessness and agitation in the elderly. Nausea and vomiting.

4.2 Posology And Method Of Administration

For all indications dosage should be individually determined, depending on the patient's response. The initiation and titration of treatment should be under close clinical supervision.

The minimum clinically effective dose should be used.

The initial dose should be determined with consideration of the patient's age, severity of symptoms and previous response to neuroleptics. In the elderly and debilitated and those with previously reported adverse reactions to neuroleptic drugs, the recommended starting dose given below should be halved. This can be gradually titrated to achieve an optimal response.

Higher doses than those recommended should only be considered in patients who have responded poorly at a lower dose.

All patients should, once control has been achieved, have their doses gradually reduced and the minimal effective mainten

1. Name Of The Medicinal Product

DOLPIN Haloperidol Oral Solution BP 10 mg/5 ml

2. Qualitative And Quantitative Composition

Each 5 ml contains 10 mg of Haloperidol

3. Pharmaceutical Form

Oral Solution

4. Clinical Particulars

4.1 Therapeutic Indications

Psychotic disorders - schizophrenia, mania and hypomania, especially paranoid psychoses. Mental or behavioural problems such as aggression, hyperactivity and self - mutilation in the mentally retarded. As an adjunct to the short term management of moderate to severe psychomotor agitation, excitement, violent or dangerously impulsive behaviour. Gilles de la Tourette syndrome, intractable hiccup and severe tics. Childhood behaviour disorders, especially when associated with hyperactivity and aggression. Restlessness and agitation in the elderly. Nausea and vomiting.

4.2 Posology And Method Of Administration

For all indications dosage should be individually determined, depending on the patient's response. The initiation and titration of treatment should be under close clinical supervision.

The minimum clinically effective dose should be used.

The initial dose should be determined with consideration of the patient's age, severity of symptoms and previous response to neuroleptics. In the elderly and debilitated and those with previously reported adverse reactions to neuroleptic drugs, the recommended starting dose given below should be halved. This can be gradually titrated to achieve an optimal response.

Higher doses than those recommended should only be considered in patients who have responded poorly at a lower dose.

All patients should, once control has been achieved, have their doses gradually reduced and the minimal effective maint

1. Name Of The Medicinal Product

Diloxanide Tablets 500mg

2. Qualitative And Quantitative Composition

Active ingredient

Quantity

Diloxanide Furoate

500 mg

3. Pharmaceutical Form

A flat, white tablet, scored and with a characteristic engraving E/F on one face.

4. Clinical Particulars

4.1 Therapeutic Indications

For the treatment of acute and chronic intestinal amoebiasis.

4.2 Posology And Method Of Administration

Adults: One tablet three times daily for ten days.

Children: 20 mg/kg bodyweight daily in divided doses for ten days. Furamide is not suitable for use in children weighing less than 25 kg.

Elderly: There is no need for dosage reduction in the elderly.

If required, a second course of treatment may be prescribed.

4.3 Contraindications

Hypersensitivity to diloxanide furoate.

4.4 Special Warnings And Precautions For Use

Keep all medicines out of the reach of children.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

No clinically-significant drug interactions known.

4.6 Pregnancy And Lactation

The safety of Furamide during pregnancy and lactation has not been establishe

1. Name Of The Medicinal Product

Dibenyline Capsules 10mg

Phenoxybenzamine 10mg Capsules

2. Qualitative And Quantitative Composition

Each capsule contains 10 mg Phenoxybenzamine hydrochloride BP.

3. Pharmaceutical Form

Capsules

4. Clinical Particulars

4.1 Therapeutic Indications

Hypertensive episodes associated with Phaeochromocytoma.

4.2 Posology And Method Of Administration

Method of Administration: Oral

Posology

Adults: The usual starting dose is 10 mg daily. This may be increased by 10 mg daily until control of hypertensive episodes is achieved, or postural hypotension occurs. Usually the dosage required is 1-2 mg/kg body weight daily in two doses. Concomitant beta-adrenergic blockade may be necessary to control tachycardia and arrythmias notably when tumours are secreting an appreciable amount of adrenaline as well as noradrenaline.

Elderly: Use with caution: 10mg daily dose should be sufficient (see Contra-Indications and Cautions below).

Children: There is little experience in children but, doses of 1 to 2 mg/kg daily have been used successfully.

4.3 Contraindications

Do not use in patients who have had a cerebrovascular accident; or in the recovery period (usually 3-4 weeks) after acute myocardial infarction.

4.4 Special Warnings And Precautions For Use

Use with great caution in patients in whom a fall in blood pressure and/or tachycardia may be undesirable, such as the elderly or those with severe heart disease, congestive heart failure, cerebrovascular di

1. Name Of The Medicinal Product

DERMAX™ THERAPEUTIC SHAMPOO

2. Qualitative And Quantitative Composition

Benzalkonium Chloride 0.5% w/w

3. Pharmaceutical Form

Clear, pale yellow to straw coloured viscous shampoo

4. Clinical Particulars

4.1 Therapeutic Indications

For the topical treatment of pityriasis capitis and other seborrhoeic scalp conditions, where there is scaling and dandruff.

4.2 Posology And Method Of Administration

For adults, children and the elderly.

Wet the hair. Apply a liberal quantity of the shampoo to the scalp and, with the tips of the fingers, rub in thoroughly. Rinse. Repeat the application and massage to produce a rich lather. Remove as much lather as possible with the hands, before rinsing thoroughly under running water.

4.3 Contraindications

Not to be used in cases of sensitivity to any of the ingredients.

4.4 Special Warnings And Precautions For Use

Keep away from the eyes.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

None known.

4.6 Pregnancy And Lactation

No special precautions.

4.7 Effects On Ability To Drive And Use Machines

None known.

4.8 Undesirable Effects

None known.

4.9 Overdose

There are no known toxic effects resulting from excessive use of Dermax Therapeutic Shampoo.

5. Pharmacological Properties

5.1 Pharmacodynamic Properties

The surface active cationic germicide, benzalkonium chloride, is adsorbed on to dry skin scales, which are a feature of pityriasis capi

1. Name Of The Medicinal Product

DDAVP®/Desmopressin Intranasal Solution

2. Qualitative And Quantitative Composition

Desmopressin acetate 0.01% w/v

3. Pharmaceutical Form

Aqueous solution for intranasal administration

4. Clinical Particulars

4.1 Therapeutic Indications

DDAVP®/Desmopressin Intranasal Solution is indicated for:

1) The diagnosis and treatment of vasopressin-sensitive cranial diabetes insipidus.

2) The treatment of nocturia associated with multiple sclerosis where other treatments have failed.

3) Establishing renal concentration capacity.

4.2 Posology And Method Of Administration

Treatment of Diabetes Insipidus:

Dosage is individual but clinical experience has shown that the average maintenance doses are as follows:

Adults: 10 to 20 micrograms once or twice daily.

Elderly: 10 to 20 micrograms once or twice daily.

Children: 5 to 20 micrograms daily, (a lower dose may be required for infants).

Diagnosis of Diabetes Insipidus:

The diagnostic dose in adults and children is 20 micrograms. Failure to elaborate a concentrated urine after water deprivation, followed by the ability to do so after the administration of Desmopressin confirms the diagnosis of cranial diabetes insipidus. Failure to concentrate after the administration suggests nephrogenic diabetes insipidus.

Treatment of nocturia:

For multiple sclerosis patients up to 65 years of age with normal renal function suffering from nocturia the dose is 10 to 20 micrograms at bed time.

Duphalac

3.35g/5ml lactulose solution

Relieves Constipation

200ml

Duphalac

3.35g/5ml, Lactulose solution

Read all of this leaflet carefully because it contains important information for you.

This medicine is available without prescription. However, you still need to take Duphalac carefully to get the best results from it.

  • Keep this leaflet. You may need to read it again.
  • Ask your pharmacist if you need more information or advice.
  • You should contact a doctor if your symptoms worsen or do not improve.
  • If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

  • 1. What Duphalac is and what it is used for
  • 2. Before you take Duphalac
  • 3. How to take Duphalac
  • 4. Possible side effects
  • 5. How to store Duphalac
  • 6. Further information

What Duphalac is and what it is used for

Duphalac contains a medicine called lactulose. This belongs to a group of medicines called laxatives.

Duphalac is used to treat constipation. It is also sometimes used to treat a liver problem called ‘hepatic encephalopathy’.

This is also known as a ‘hepatic coma’.

Before you take Duphalac

1. Name Of The Medicinal Product

Diazepam Injection BP.

2. Qualitative And Quantitative Composition

Each ml contains 5 mg of Diazepam.

3. Pharmaceutical Form

Sterile injection.

4. Clinical Particulars

4.1 Therapeutic Indications

Diazepam is an anxiolytic, anticonvulsant and central muscle-relaxant. Diazepam is used to relieve anxiety and provide sedation in severe acute anxiety or agitation and for the management of agitation associated with delirium tremens.

Diazepam is used to relieve acute muscle spasm and tetanus.

Acute convulsions including status epilepticus, also convulsions due to poisoning and febrile convulsions. As an adjunct during endoscopy, in dentistry, surgery, radiology. Cardiac catheterisation, cardioversion, used pre-operatively to relieve anxiety, provide sedation, light anaesthesia and anterograde amnesia.

4.2 Posology And Method Of Administration

Diazepam Injection BP may be given IV, IM or by IV infusion.

Adults:

Severe acute anxiety or agitation:

10 mg IV or IM injection

which may be repeated after an interval of not less than 4 hours.

Delirium Tremens:

10 – 20 mg IV or IM.

Higher doses may be needed depending on severity of symptoms.

Acute Muscle Spasm:

10 mg IV or IM injection

which may be repeated after an interval of not less than 4 hours.

Tetanus:

Initially an IV dose of 0.1 - 0.3 mg/kg body weight, repeated at intervals of 1 - 4 hours. Continuous IV infusion of 3 – 10 mg/kg body weight per 24 hours can also be used. The chosen dose should be related

1. Name Of The Medicinal Product

Diazepam RecTubes 2.5mg Rectal Solution

2. Qualitative And Quantitative Composition

Diazepam 2.5mg in 1.25ml

(2mg/ml)

For excipients, see 6.1

3. Pharmaceutical Form

Rectal solution

A clear, colourless or almost yellow solution

4. Clinical Particulars

4.1 Therapeutic Indications

Diazepam rectal tubes may be used in severe or disabling anxiety and agitation; epileptic and febrile convulsions; to relieve muscle spasm caused by tetanus; as a sedative in minor surgical and dental procedures, or other circumstances in which a rapid effect is required but where intravenous injection is impracticable or undesirable.

Diazepam rectal tubes may be of particular value for the immediate treatment of convulsions in children.

4.2 Posology And Method Of Administration

Dosage depends on age and weight.

Children:

0.5mg/kg

(not recommended for use in children less than one year old)

Adults:

0.5mg/kg

If convulsions are not controlled other anticonvulsive measures should be instituted.

1. Name Of The Medicinal Product

Ledermycin Capsules 150mg

Demeclocycline Hydrochloride 150mg Capsules

2. Qualitative And Quantitative Composition

LEDERMYCIN capsules each contain 150mg of demeclocycline hydrochloride.

3. Pharmaceutical Form

capsule, hard

4. Clinical Particulars

4.1 Therapeutic Indications

For the treatment of infections caused by tetracycline-sensitive organisms. For example, LEDERMYCIN is highly effective in the treatment of infections caused by Borrelia recurrentis (relapsing fever), Calymmatobacterium granulinatis (granuloma inguinale), Chlamydia species (psittacosis, lymphogranuloma vereneum, trachoma, inclusion conjunctivitis), Francisella tularensis (tularaemia), Haemophilus ducreyi (chancroid), Leptospira (meningitis, jaundice), Mycoplasma pneumoniae (non-gonococcal urethritis), Pseumomonas mallei and pseudomallei (glanders and melioidosis), Rickettsiae (typhus fever, Q fever, rocky mountain spotted fever), Vibrio species (cholera). It is also highly effective, alone or in combination with streptomycin, in the treatment of infections due to Brucella species (brucellosis) and Yersinia pestis (bubonic plague). Severe acne vulgaris.

Other sensitive organisms include: Actinomyces israelii, Bacillus anthracis (pneumonia), Clostridium species (gas gangrene, tetanus), Entamoeba histolytica (dysentery), Neisseria gonorrhoeae and anaerobic species, Treponema pallidum and pertenue (syphilis and yaws).

For the treatment of chronic hyponatraemia associated with the syndrome of inappropriate secretion of antidiuret

1. Name Of The Medicinal Product

Dipentum Capsules 250 mg

Dipentum Tablets 500 mg

2. Qualitative And Quantitative Composition

Each capsule contains 250mg olsalazine sodium.

Each tablet contains 500mg olsalazine sodium.

For excipients, see 6.1.

3. Pharmaceutical Form

Capsule, hard

Tablets

4. Clinical Particulars

4.1 Therapeutic Indications

Oral treatment of mild active ulcerative colitis and maintenance of remission.

4.2 Posology And Method Of Administration

Oral.

General

Olsalazine taken on an empty stomach may sometimes lead to loose stools or diarrhoea. By taking the drug at the end of a meal, this may be avoided.

Acute Mild Disease

Adults including the elderly: Commence on 1 g daily in divided doses taken at the end of meals. Depending on the patient's response, the dose may be titrated upwards over a period of one week to a maximum of 3g daily.

A single dose should not exceed 1 g.

Remission

Adults including the elderly:A dose of 0.5g should be taken twice daily, at the end of meals.

Olsalazine has been used concomitantly with gluco-corticosteroids.

4.3 Contraindications

Hypersensitivity to olsalazine or other salicylates or any other of the excipients.

There is no experience of the use of olsalazine in patients with significant renal impairment. Olsalazine is contra-indicated in patients with significant renal impairment.

4.4 Special Warnings And Precautions For Use

1. Name Of The Medicinal Product

Desferrioxamine Mesilate for Injection BP 500 mg and 2 g

2. Qualitative And Quantitative Composition

Desferrioxamine mesilate 500 mg or 2 g per vial

Following reconstitution with 5 ml (500 mg vial) or 20 ml (2 g vial) Water for Injections, each ml of solution contains 100 mg desferrioxamine mesilate.

3. Pharmaceutical Form

Powder for solution for injection

Vails containing a white to cream powder or lyophilised plug.

4. Clinical Particulars

4.1 Therapeutic Indications

Iron overload - acute iron poisoning; primary and secondary haemochromatosis including thalassaemia and transfusional haemosiderosis; in patients in whom concomitant disorders (e.g. severe anaemia, hypoproteinaemia, renal or cardiac failure) preclude phlebotomy; and for the diagnosis of iron storage disease and certain anaemias.

Aluminium overload - in patients on maintenance dialysis for end stage renal failure where preventative measures (e.g. reverse osmosis) have failed and with proven aluminium-related bone disease and/or anaemia, dialysis encephalopathy; and for diagnosis of aluminium overload

4.2 Posology And Method Of Administration

Desferrioxamine mesilate may be administered parenterally, or orally (for acute iron poisoning only).

Desferrioxamine has limited efficacy in children under three years of age.

Preparation:For parenteral administration: The drug should preferably be employed in the form of a 10 % solution, e.g. by dissolving the contents of one 500 mg vial in 5 ml of Water for Injections. When administered subcutaneously the needle should not be inserted too close to the dermis. The 10 % desferrioxamine mesilate sol